BG · available-data snapshot
Bunge Global SA (BG): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Bunge Global SA (BG); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for BG?
We do not publish a fair value for Bunge Global SA. What we can say from its filings and market data is below.
What is BG's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Consumer Defensive companies in US
Its strongest point: trades below our estimate of what it's worth. Its weakest: profitability is weak.
- Value · 62 of 100
Cheaper than 62% of Consumer Defensive companies in US
- Price vs worth · 100 of 100
- Quality · 13 of 100
More profitable than 13% of Consumer Defensive companies in US
- Financial health · 38 of 100
Financially stronger than 38% of Consumer Defensive companies in US
- Growth · 91 of 100
Growing faster than 91% of Consumer Defensive companies in US
- Momentum · 27 of 100
Outperformed 27% of Consumer Defensive companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $102.77
- Market cap
- $19,
744, 081, 920 - 52-week high
- $134.87
- 52-week low
- $88.24
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Bunge Global SA (BG) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, BG trades at a recent price of $102.77, a market capitalisation of about $19,744,081,920, sitting 31% of the way up its 52-week range ($88.24–$134.87), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing BG's trading multiples against a sector benchmark. Here that gives P/E of 20.5× (cheaper than the peer median of 28.2×); Fwd P/E of 9.2× (cheaper than the peer median of 26.7×); P/B of 1.2× (cheaper than the peer median of 9.6×); P/S of 0.2× (cheaper than the peer median of 1.8×); EV/EBITDA of 12.2× (cheaper than the peer median of 23.0×); Dividend yield of 2.8% (cheaper than the peer median of 2.3%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. BG shows a price-to-book (P/B) of 1.24 and book value of $83.04 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. BG is in a down-trend (price below both its 50- and 200-day averages), trading -23.8% from its 52-week high. Over the past year the stock is +9.1%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
BG vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | BG | Peer median | Read |
|---|---|---|---|
| P/E | 20.5× | 28.2× | cheaper than |
| Fwd P/E | 9.2× | 26.7× | cheaper than |
| P/B | 1.2× | 9.6× | cheaper than |
| P/S | 0.2× | 1.8× | cheaper than |
| EV/EBITDA | 12.2× | 23.0× | cheaper than |
| Dividend yield | 2.8% | 2.3% | cheaper than |
What does Bunge Global SA do?
What does it do?
Bunge Global SA operates as an agribusiness and food company worldwide. It operates through four segments: Soybean Processing and Refining, Softseed Processing and Refining, Other Oilseeds Processing and Refining, and Grain Merchandising and Milling. It operates in the Farm Products industry (Consumer Defensive sector), headquartered in United States. The company employs roughly 34,000 people.
How does it make money?
The business turns $16.9B in annual revenue into profit. Out of every $100 of sales, about $5 is left as operating profit (operating margin of 4.6%), after a 5% gross margin on the products/services it sells. After all costs, taxes and interest, 1.1% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (1.0× equity), comfortably covers its short-term bills (1.6× current ratio), and is currently profitable.
Who at BG filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Isman Adrian | Director | Grant / award | $1,192.50 | Form 4 for Isman Adrian (opens sec.gov in a new tab) | |
| Dimopoulos Christos | EVP and CSO | Grant / award | $19,080.00 | Form 4 for Dimopoulos Christos (opens sec.gov in a new tab) | |
| McGurk Monica Houle | Director | Grant / award | $1,192.50 | Form 4 for McGurk Monica Houle (opens sec.gov in a new tab) | |
| Sears Kellie | Chief Human Resources Officer | Grant / award | $13,952.25 | Form 4 for Sears Kellie (opens sec.gov in a new tab) | |
| Zenuk Mark N | Director | Grant / award | $2,385.00 | Form 4 for Zenuk Mark N (opens sec.gov in a new tab) | |
| Podwika Joseph | Chief Legal Officer | Grant / award | $16,575.75 | Form 4 for Podwika Joseph (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.